# Peg Interferon α-2b for Relapsed Hematological Malignancies After Allo-HSCT

> **NCT02634294** · PHASE2,PHASE3 · COMPLETED · sponsor: **Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine** · enrollment: 30 (actual)

## Conditions studied

- Hematological Neoplasms
- Recurrence

## Interventions

- **DRUG:** Peg interferon alfa-2b

## Key facts

- **NCT ID:** NCT02634294
- **Lead sponsor:** Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-08
- **Primary completion:** 2021-12
- **Final completion:** 2021-12
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2023-03-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02634294

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02634294, "Peg Interferon α-2b for Relapsed Hematological Malignancies After Allo-HSCT". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT02634294. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*